Infection

Fresh Bros: Exploring the Top Five Health Benefits of Turmeric Extract with BioPerine

Retrieved on: 
Wednesday, October 27, 2021
People, Woman, Depression, Arthritis, Degenerative disease, Neuron, Allergy, Herbal, Infection, BDNF, Time-invariant system, Osteoarthritis, Athlete, Piperine, Brain, Curcumin, Oxidative stress, Absorption, Ageing, Growth, Chemistry (relationship), Stroke, Farm, Cell, Laboratory, Rheumatoid arthritis, GLOBE, Medicinal plants, Spice, Dietary supplement

Fresh Bros now stock Turmeric (Curcumin) Extract with BioPerine .

Key Points: 
  • Fresh Bros now stock Turmeric (Curcumin) Extract with BioPerine .
  • BioPerine is a patented piperine extract, containing at least 95% piperine in a form that is readily absorbed by your body.
  • Fresh Bros put this in their turmeric extract to improve the bioavailability and absorption of the turmeric so you get the full benefit of this wonderful spice.
  • Fresh Bros sells the freshest organically grown hemp and CBD wholesale products from USA farms and laboratories, including turmeric (curcumin) extract with BioPerine.

emocha Health Awarded Video Directly Observed Therapy Contract by Texas Department of State Health Services

Retrieved on: 
Wednesday, October 27, 2021
VPS Healthcare, Johns Hopkins, Travel, Patient, View, Strategic partnership, RFP, Review, DOT, VP, Infection, TB, COVID-19, Multimedia, Public health, Health, Diabetes, Population, Tuberculosis, Coronavirus, Asthma, Pharmaceutical industry

emocha Health has supported health departments and their patients across Texas for more than six years.

Key Points: 
  • emocha Health has supported health departments and their patients across Texas for more than six years.
  • emocha, a Johns Hopkins spin-out, began its work in Texas with a pilot of its video DOT application in Harris County.
  • In 2020, during the COVID-19 pandemic, Texas reached out to all potential Video DOT providers it was aware of, including emocha Health, to provide additional emergency video DOT support to rural TB patients statewide.
  • With the addition of the state-wide Texas contract, emocha Health is now delivering video DOT to over 500 public health departments across the United States.

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

Retrieved on: 
Wednesday, October 27, 2021
Safety, Donnelly (surname), Compliance, Research, Academy, CSE, Patient, QUB, FDA, Holding, Infection, OTCQB, Ketamine, Doctor of Philosophy, BBSRC, Mental health, CEO, Trial of the century, Pharmaceutics, GLOBE, Pharmacy, Vaccine, Pharmaceutical industry

TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce the appointment of Professor Ryan Donnelly, a world leader in the research and development of microneedle delivery technologies, as scientific and technical advisor for PharmaThers microneedle patch delivery programs involving controlled-substances such as ketamine and compounds treating infectious diseases.

Key Points: 
  • TORONTO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce the appointment of Professor Ryan Donnelly, a world leader in the research and development of microneedle delivery technologies, as scientific and technical advisor for PharmaThers microneedle patch delivery programs involving controlled-substances such as ketamine and compounds treating infectious diseases.
  • Professor Donnelly's lab successfully completed research and published a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery.
  • He is a leading expert and researcher in the field of transdermal delivery with a primary focus on microneedle drug delivery and its applications on improving therapeutic outcomes for patients.
  • Professor Ryan Donnelly commented, "I am delighted to expand my role with PharmaTher in the research, development and manufacturing of a next generation microneedle patch for the intradermal delivery of controlled-substances and compounds to treat infectious diseases.

Eldorado Gold Announces Closing of Tocantinzinho Sale to G Mining Ventures

Retrieved on: 
Wednesday, October 27, 2021
EDGAR, Goal, Private Securities Litigation Reform Act, SEDAR, Risk, Nature, Life, Infection, Forward-looking statement, Company, Phrase, TZ, COVID-19, Chemistry (relationship), Gold, Risk factor, Metal, Public relations, Audit

In particular, except where otherwise stated, we have assumed a continuation of existing business operations on substantially the same basis as exists at the time of this release.

Key Points: 
  • In particular, except where otherwise stated, we have assumed a continuation of existing business operations on substantially the same basis as exists at the time of this release.
  • There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
  • Accordingly, you should not place undue reliance on the forward-looking statements or information contained herein.
  • Except as required by law, we do not expect to update forward-looking statements and information continually as conditions change.

PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference

Retrieved on: 
Wednesday, October 27, 2021
Head, Biotechnology, Immunotherapy, PDSB, Vaccine, Disease, Prostate, McGovern Medical School, Twitter, Communication, Nature, National, COVID-19, Immune system, Food and Drug Administration, GLOBE, Informatics, Health, HIV, Lung, Research, Circle, Food, Infection, Company, PDS, National Cancer Institute, Fellowship of the Royal Colleges of Surgeons, Goal, Medical director, Health informatics, Breast, Cancer, SEC, Center, Hospital, Nasdaq, Risk, Colon, HER, Technology, University, Harvard Medical School, Knowledge, Wales, Patient, Review, TARP, Conference, Forward-looking statement, American College, American Board of Commissioners for Foreign Missions, Lowell, Pharmaceutical industry, Animal

Dr. Lauren V. Wood will be joining Dr. Arthur M. Lauretano in hosting the 90-minute seminar titled New Drugs in the Fight Against Head & Neck Cancer.

Key Points: 
  • Dr. Lauren V. Wood will be joining Dr. Arthur M. Lauretano in hosting the 90-minute seminar titled New Drugs in the Fight Against Head & Neck Cancer.
  • Dr. Wood will highlight the potential impact of the Companys proprietary, Versamune T-cell activating technology on the treatment of HPV-associated head and neck cancer with PDS0101.
  • Details for the conference and seminar are as follows:
    2021 International Head and Neck Cancer Conference:
    Dr. Wood and Dr. Lauretano both bring a breadth of knowledge and experience to the table.
  • Dr. Wood joined PDS Biotech as Chief Medical Officer in February 2019.

Insights on the Probiotics Global Market to 2026 - Featuring Alltech, Kerry Group and Nestle Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 27, 2021
Food, Beverage, Retail, Probiotic, USD, Technology, Decision-making, Certification, Strategic management, Value, Infection, Customer support, Business Growth Fund, Investment, Market share analysis, Mergers and acquisitions, Growth, COVID-19, CAGR, Use, News, R, Acquisition, Collaborative partnership, Retail, Dietary supplement

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Key Points: 
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Probiotics Market during the forecast period?
  • What is the market share of the leading vendors in the Global Probiotics Market?
  • What modes and strategic moves are considered suitable for entering the Global Probiotics Market?

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

Retrieved on: 
Wednesday, October 27, 2021
Research, Infectious Diseases, FDA, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Vitamin, Infection, Medication, Research, Dexamethasone, Defense, Plasma protein binding, Tablet, Munitions Safety Information Analysis Center, Common stock, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, FDA, NYSE, Food, United States Department of Veterans Affairs, 340B Drug Pricing Program, Degenerative disease, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Department of Defense Architecture Framework, Annual report, Forward-looking statement, Veterans' affairs, Company, Investment, Potassium, COVID-19, Growth, HPA, Packager, Central nervous system, Ownership, Department, Abbreviated New Drug Application, Sodium, ANDA, Pharmaceutical industry, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).
  • Dexamethasone, the generic version of Decadron, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.
  • Todays approval and launch of dexamethasone reflects the continued execution of our innovation agenda.
  • Dexamethasone tablets can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency.

SilverSneakers Offers Innovative Virtual Programs, Expanded Premium Network in 2022

Retrieved on: 
Wednesday, October 27, 2021
Well, FLEX, Research, Compliance, Securities Act of 1933, Disease, Contract, Failure, Medicare Advantage, Medigap, Security (finance), Tivity Health, U.S. Securities and Exchange Commission, Insurance, Duke Diet and Fitness Center, Legislation, Pandemic, Infection, SEC, Risk, Marketing, Company, Phrase, Ageing, Disclosure, CEO, COVID-19, Multimedia, Social engagement, Program, Friends, Epidemic, Solution, Health, Nasdaq, Employee Retirement Income Security Act of 1974, Privacy, Securities Exchange Act of 1934, Longevity, Health insurance, Medicine, Online shopping

Broad and Flexible Fitness Network Options -- SilverSneakers will offer a customizable network of more than 22,000 fitness locations, including options for studio fitness from some of the most recognizable brands.

Key Points: 
  • Broad and Flexible Fitness Network Options -- SilverSneakers will offer a customizable network of more than 22,000 fitness locations, including options for studio fitness from some of the most recognizable brands.
  • Virtual Fitness -- SilverSneakers members will have access to approximately 2,000 live with instructor classes per week in a variety of lengths and formats, as well as the SilverSneakers OnDemand library.
  • In addition, SilverSneakers will offer mental enrichment for seniors with opportunities to stay intellectually engaged and maintain brain health through virtual classes and activities.
  • A recent SilverSneakers Pulse Survey of more than 1,000 members, found that about half of all respondents have participated in SilverSneakers virtual exercise.

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

Retrieved on: 
Wednesday, October 27, 2021
Safety, Financial condition report, CMA, Chemistry, Biotechnology, Volunteering, COVID-19, Disease, Antigen presentation, Nanoparticle, Global health, Vaccination, Novavax COVID-19 vaccine, COVID-19 vaccine, File, Health care, Analysis, Security (finance), Partnership, U.S. Securities and Exchange Commission, Patient, World Health Organization, FDA, World, Result, Conditional, Severe acute respiratory syndrome coronavirus 2, SEC, Review, Non-governmental organization, Lymph, CMC, Infection, Genetic engineering, United Kingdom, Risk, Annual report, Conversation, Clinical trial, Vaccine, Multimedia, B cell, Program, Health, MHRA, Serum Institute of India, NVAX, Coronavirus, B.1.1.7, Pharmaceutical industry

Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.

Key Points: 
  • Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.
  • The company's application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.
  • "We look forward to MHRA's review and will be prepared to deliver vaccine doses following what we anticipate will be a positive decision.
  • We thank the clinical trial participants and trial sites in the United Kingdom, as well as the U.K.

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

Retrieved on: 
Wednesday, October 27, 2021
Safety, Financial condition report, CMA, Chemistry, Biotechnology, Volunteering, COVID-19, Disease, Antigen presentation, Nanoparticle, Global health, Vaccination, Novavax COVID-19 vaccine, COVID-19 vaccine, File, Health care, Analysis, Security (finance), Partnership, U.S. Securities and Exchange Commission, Patient, World Health Organization, FDA, World, Result, Conditional, Severe acute respiratory syndrome coronavirus 2, SEC, Review, Non-governmental organization, Lymph, CMC, Infection, Genetic engineering, United Kingdom, Risk, Annual report, Conversation, Clinical trial, Vaccine, Multimedia, B cell, Program, Health, MHRA, Serum Institute of India, NVAX, Coronavirus, B.1.1.7, Pharmaceutical industry

Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.

Key Points: 
  • Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.
  • The company's application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.
  • "We look forward to MHRA's review and will be prepared to deliver vaccine doses following what we anticipate will be a positive decision.
  • We thank the clinical trial participants and trial sites in the United Kingdom, as well as the U.K.